Company Overview - Aipeng Medical's closing price on April 3 was 23.56 yuan, down 3.28%, with a rolling PE ratio of 561.71 times and a total market value of 2.97 billion yuan [1] - The company operates in the medical device sector, focusing on pain management and upper respiratory tract management, with key products including microcomputer infusion pumps and wireless pain management systems [1] Financial Performance - For the third quarter of 2024, Aipeng Medical reported revenue of 275 million yuan, a year-on-year decrease of 7.12%, and a net profit of 3.81 million yuan, down 43.99% [2] - The company's gross profit margin stood at 69.02% [2] Market Position - In terms of PE ratio, Aipeng Medical ranks 120th in the medical device industry, which has an average PE of 46.48 times and a median PE of 31.96 times [1][2] - As of the third quarter of 2024, seven institutions held shares in Aipeng Medical, with a total of 755,600 shares valued at 1.3 million yuan [1] Awards and Recognition - The company's brand, Nosqing, received the "West Lake Award: Innovative Marketing" at the Wuzhen Health Conference and was recognized as the "Most Popular Star Product in Pharmacies" for two consecutive years [1] - Nosqing also won the "Most Cooperative Value Product in Chinese Chain Pharmacies" at the 2024 Misi Conference [1]

3月28日，爱朋医疗今日收盘22.07元，下跌3.54%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到526.19倍，总市值27.82亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均45.22倍，行业中值32.57倍，爱朋医疗排 名第120位。 截至2024年三季报，共有1家机构持仓爱朋医疗，其中基金1家，合计持股数0.16万股，持股市值0.00亿 元。 江苏爱朋医疗科技股份有限公司的主营业务是疼痛管理、鼻腔及上气道管理细分领域用医疗器械研发、 生产、销售以及相关医疗器械CXO服务，主要产品包括微电脑注药泵、无线镇痛管理系统、麻醉深度 监测仪、高渗缓冲海水鼻腔护理喷雾器、弱酸性缓冲生理海水鼻腔护理喷雾器、"敏伴"复合益生菌粉固 体饮料、安波澜便携多导睡眠记录系统、医疗器械设备CXO。报告期内，诺斯清品牌获乌镇健康大 会"西湖奖·创新营销"奖项，并二次蝉联"西湖奖·最受药店欢迎的明星单品"。诺斯清产品再获2024米思 会-中国医药健康产业共生大会"中国连锁药店最具合作价值单品"。 最新一期业绩显示，2024年三季报，公司实现营业收入2.75亿元，同比-7.12%；净利润380.73 ...

爱朋医疗实控人减持受限借道协议转让 接盘方章泓 私募基金有没有过桥特征？ 出品：新浪上市公司研究院 文/夏虫工作室 近日，协议转让疑似迎来强监管引发市场关注。 根据相关媒体公开报道，监管下发以协议转让方式违规减持线索筛查指引（试行）（以下简称：指 引文件）相关文件，剑指借道协议转让实现违规减持套现问题。据了解，筛查指引主要内容针对以下八 大情形： 即转让双方是否存在高度可疑的密切关联；出让方是否触及减持限制情形；受让方是否存在过桥通 道特征；协议转让交易背景是否真实；资金来源匹配性是否存疑；支付安排是否合理；锁定期满后是否 即刻减持或清仓减持；协议转让后股价是否明显异动等。 来源：公开报道 在"最严"减持新规的背景下，有越来越多的上市公司却选择协议转让。据wind不完全统计，剔除协 议转让失败的，完成或正在进行协议转让上市公司超140家。在减持新规压力下，协议转让究竟是股东 合规退出通道还是违规套现新套路？ 基于以上一些列疑问，结合此次监管协议转让违规减持线索筛查指引，我们将对个股协议转让进行 深度复盘，看看哪些公司可能涉嫌借道协议转变相违规套现？ 实控人减持疑似受限 协议转让给私募基金 爱朋医疗于2018年 ...

江苏爱朋医疗科技股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 股票交易异常波动的情况介绍 江苏爱朋医疗科技股份有限公司（以下简称"公司"）股票交易价格于2025年3月18日、 2025年3月19日、2025年3月20日连续三个交易日内收盘价格涨幅偏离值累计超过30%。根 据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实情况说明 针对公司股票交易异常波动，公司董事会对公司、控股股东及实际控制人就相关事项 进行了核实，现就有关情况说明如下： 证券代码：300753 证券简称：爱朋医疗 公告编号：2025-002 6、公司不存在违反信息公平披露的情形。 三、是否存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据《深圳证券交易所创业板股票上市规则》 等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议等；董 事会也未获悉本公司有根据《深圳证券交易所创业板股票上市规则》等有关规定应予以披 露而未披露的、对本公司股票及其衍生品种交易价格产生较大影响的 ...

Group 1 - The blood oxygen monitor concept index rose by 0.71%, ranking 7th among concept sectors, with 6 stocks increasing in value, including Huashengchang which hit the daily limit, and Aipeng Medical, Jiahe Intelligent, and Zhongyuan Co., which rose by 15.88%, 3.76%, and 3.30% respectively [1] - The stocks with the largest declines included Zhongke Meiling, Yitong Technology, and Kexiang Co., which fell by 7.31%, 4.22%, and 1.88% respectively [1] Group 2 - The blood oxygen monitor concept sector experienced a net outflow of 85 million yuan in main funds, with 7 stocks seeing net inflows, and 5 stocks receiving over 10 million yuan in net inflows [1] - The stock with the highest net inflow was Fenda Technology, which saw a net inflow of 106 million yuan, followed by Jiahe Intelligent, Aipeng Medical, and Zhongyuan Co., with net inflows of 88.76 million yuan, 82.06 million yuan, and 19.54 million yuan respectively [1] Group 3 - In terms of fund inflow ratios, Jiahe Intelligent, Aipeng Medical, and Huashengchang had the highest inflow ratios, with net inflow rates of 11.16%, 9.45%, and 6.63% respectively [1]

Group 1 - The brain-computer interface (BCI) sector is experiencing active performance, with companies like Aipeng Medical and Innovation Medical seeing significant stock increases, indicating a potential explosive growth phase for the industry [1] - A research team led by Professor Jin Jing from East China University of Science and Technology has developed a new mixed-reality enhanced BCI system for quadruped control, which integrates mixed reality technology with BCI for efficient and stable control of robotic dogs [1][2] - The traditional BCI systems face challenges in real-world applications, such as environmental light interference and poor portability, which limit their performance and application range. The new framework proposed by Jin's team aims to enhance BCI systems with features like anti-interference, high performance, and portability [1] Group 2 - The rapid development of BCI technology is supported by advancements in artificial intelligence, neuroscience, and sensors, with China's "14th Five-Year Plan" designating "brain science and brain-like research" as a key frontier technology project [2] - The global market for BCI technology is projected to reach $1.98 billion in 2023 and exceed $6 billion by 2028, with a compound annual growth rate of 25.22% over five years [2] - China is making significant strides in non-invasive BCI technology, with policies supporting the industry and a goal to achieve core technology autonomy and clinical application by 2030 [2][3] Group 3 - The BCI industry is witnessing breakthroughs in applications such as motor recovery, language communication, and hearing restoration, driven by technological advancements and supportive national policies [3] - Recent policy initiatives, including the National Medical Insurance Administration's decision to separately list new BCI technology pricing, are paving the way for clinical application and service charge pathways [3] - Domestic BCI companies are expected to gradually achieve commercialization due to technological innovations and policy incentives [3]

证券代码：300753 证券简称：爱朋医疗 江苏爱朋医疗科技股份有限公司 投资者关系活动记录表 编号：2025-002 | | 特定对象调研 分析师会议 | | --- | --- | | 投资者关系活动 | 媒体采访 业绩说明会 | | 类别 | 新闻发布会 路演活动 | | | 现场参观 | | | 其他（电话会议） | | | 中信建投证券吴严，中信建投证券徐超，华西证券赵晓燕，天风资管 许磊涛，上海烜鼎私募基金谭鹏，上海弈术投资孙宏廷，上海惠璞投 | | 参与单位名称及 | 资徐克，汇鸿汇升投资赵晓宇，理石投资宋雅晴，海南无量私募基金 | | 人员姓名 | 何晶，重庆钧山投资敖焱杰，中财招商投资集团朱凌云，上海久有私 | | | 募基金丁剑锋，上海智晶私募基金薛伟杰，上海国鸣投资张同鑫，上 | | | 海默驰投资刘猛，上海前点投资袁佳，浙江弘悦私募基金聂磊等 25 人 | | 时间 | 2025 年 2 月 19 日 15:00-17:00 | | 地点 | 爱朋医疗上海会议室现场 | | 上市公司接待人 员姓名 | 董事会秘书叶俞飞先生，证券事务代表黄秀秀女士 | 投资者关系活动主要 ...

投资者关系活动主要内容介绍 证券代码：300753 证券简称：爱朋医疗 江苏爱朋医疗科技股份有限公司 投资者关系活动记录表 编号：2025-001 | | 特定对象调研 分析师会议 | | | --- | --- | --- | | 投资者关系活动 | 媒体采访 | 业绩说明会 | | 类别 | 新闻发布会 路演活动 | | | | 现场参观 | | | | 其他（电话会议） | | | | 中信建投王在存，中信建投刘慧彬，中信建投华冉，国泰基金邱晓旭， 国泰基金王彧，源乐晟基金欧阳明，源乐晟基金吴海燕，源乐晟基金 | | | 参与单位名称及 | 王可蓥，人保养老基金于秋萍，人保养老基金毛雅婷；天风证券周海 | | | 人员姓名 | 涛，湘财证券蒋栋，永赢基金张蕊，永赢基金单林，国联安基金赵子 | | | | 淇，深积资产杨森，德邦基金揭诗琪，浦银安盛基金张瑞，鹤禧投资 | | | | 吴迪龙等 19 人 | | | 时间 | 10:00-17:00 | | | | 2025 年 1 月 3 日 | | | 地点 | 网络电话会议；爱朋医疗上海会议室现场 | | | 上市公司接待人 | 董事长 ...

Government and Industry Collaboration - Encourage collaboration between national laboratories, research institutions, and medical institutions in Shanghai to achieve leading and disruptive theoretical results [1] Medical AI Development Plan - Shanghai Municipal Government issued the "Shanghai Medical Artificial Intelligence Work Plan (2025-2027)" on December 24, focusing on advancing research in AI cognitive intelligence and reinforcement learning [2] - Support innovative exploration in frontier medical fields such as brain science, brain-computer interfaces, and computational biology [2] Market Performance - Brain engineering concept stocks strengthened, with Aipeng Medical rising over 6%, Fudan Forward rising 5%, and Weisi Medical rising nearly 4% [2]

江苏爱朋医疗科技股份有限公司 关于控股股东、实际控制人协议转让公司部分股份 完成过户登记的公告 证券代码：300753 证券简称：爱朋医疗 公告编号：2024-048 本次协议转让股份过户登记前后，各方股份变动情况如下： 注：1、本公告中，占总股本比例数值按四舍五入精确到小数点后两位。若出现各分项数值之和与 总数尾数不符的情况，均为四舍五入原因造成。 2、以上有限售条件股份为高管锁定股。 公司控股股东、实际控制人王凝宇先生保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）于近日收到控股股东、实际控 制人王凝宇先生以及北京章泓私募基金管理有限公司（代表"章泓精选 1 号私募证券投资 基金"）（以下简称"章泓基金"）的通知，王凝宇先生通过协议转让方式向章泓基金转 让其持有的 7,058,000 股公司无限售流通股事项已完成证券过户登记手续。现将具体情况公 告如下： 一、本次协议转让的基本情况 王凝宇先生与章泓基金于 2024 年 9 月 29 日签署了《关于江苏爱朋 ...